Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score.

Klein, Piers; Shu, Liqi; Nguyen, Thanh N; Siegler, James E; Omran, Setareh Salehi; Simpkins, Alexis N; Heldner, Mirjam; Havenon, Adam de; Aparicio, Hugo J; Abdalkader, Mohamad; Psychogios, Marios; Vedovati, Maria Cristina; Paciaroni, Maurizio; von Martial, Rascha; Liebeskind, David S; Sousa, Diana Aguiar de; Coutinho, Jonathan M; Yaghi, Shadi (2022). Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score. Journal of stroke, 24(3), pp. 404-416. Korean Stroke Society 10.5853/jos.2022.01606

Preview

Text jos-2022-01606.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (166kB) | Preview

BACKGROUND

We identified risk factors, derived and validated a prognostic score for poor neurological outcome and death for use in cerebral venous thrombosis (CVT).

METHODS

We performed an international multicenter retrospective study including consecutive patients with CVT from January 2015 to December 2020. Demographic, clinical, and radiographic characteristics were collected. Univariable and multivariable logistic regressions were conducted to determine risk factors for poor outcome, mRS 3-6. A prognostic score was derived and validated.

RESULTS

A total of 1,025 patients were analyzed with median 375 days (interquartile range [IQR], 180 to 747) of follow-up. The median age was 44 (IQR, 32 to 58) and 62.7% were female. Multivariable analysis revealed the following factors were associated with poor outcome at 90- day follow-up: active cancer (odds ratio [OR], 11.20; 95% confidence interval [CI], 4.62 to 27.14; P<0.001), age (OR, 1.02 per year; 95% CI, 1.00 to 1.04; P=0.039), Black race (OR, 2.17; 95% CI, 1.10 to 4.27; P=0.025), encephalopathy or coma on presentation (OR, 2.71; 95% CI, 1.39 to 5.30; P=0.004), decreased hemoglobin (OR, 1.16 per g/dL; 95% CI, 1.03 to 1.31; P=0.014), higher NIHSS on presentation (OR, 1.07 per point; 95% CI, 1.02 to 1.11; P=0.002), and substance use (OR, 2.34; 95% CI, 1.16 to 4.71; P=0.017). The derived IN-REvASC score outperformed ISCVT-RS for the prediction of poor outcome at 90-day follow-up (area under the curve [AUC], 0.84 [95% CI, 0.79 to 0.87] vs. AUC, 0.71 [95% CI, 0.66 to 0.76], χ2 P<0.001) and mortality (AUC, 0.84 [95% CI, 0.78 to 0.90] vs. AUC, 0.72 [95% CI, 0.66 to 0.79], χ2 P=0.03).

CONCLUSIONS

Seven factors were associated with poor neurological outcome following CVT. The INREvASC score increased prognostic accuracy compared to ISCVT-RS. Determining patients at highest risk of poor outcome in CVT could help in clinical decision making and identify patients for targeted therapy in future clinical trials.

Interest & Impact

Downloads

17 since deposited on 13 Oct 2022
17 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item